Vanguard Information Technology Index Fund ETF vs Zoetis Inc — how do they compare? Vanguard Information Technology Index Fund ETF trades at $121.67, while Zoetis Inc trades at $73.8 (market cap $31.14B). The key difference: Zoetis Inc pays a 2.81% dividend while Vanguard Information Technology Index Fund ETF pays none, and Vanguard Information Technology Index Fund ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| VGT | ZTS | |
|---|---|---|
52-Week High | $125.77 | $156.76 |
52-Week Low | $83.59 | $71.91 |
Market Cap | — | $31.14B |
Sector | — | Health |
Enterprise Value | — | $38.70B |
Dividend Yield | — | 2.81% |
Signals from Pluang's Aura AI — not financial advice
Vanguard Information Technology ETF (VGT) trades at $121.60, up 1.12% with strong technical momentum as moving averages signal bullish sentiment. The ETF benefits from institutional accumulation and AI-driven technology sector strength, though RSI levels indicate potential near-term overbought conditions. Recent news highlights VGT's pure tech focus and outperformance versus broader tech ETFs.
VGT offers concentrated exposure to AI infrastructure leaders with strong institutional backing, but faces risks from sector concentration and valuation pressures. The ETF's momentum-driven returns depend on continued technology sector leadership, particularly in semiconductor and cloud computing segments where earnings growth remains robust.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Trailing returns across standard periods
Latest headlines on both assets
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →